TapewireFind a company

person · Reporting owner

Dake Benjamin T

Disclosed activity across 1 company

Tapewire entity
88536
SEC CIK
0001869248

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Jade Biosciences, Inc.AVTE · Entity 4757SEE REMARKSJuly 31, 2024August 02, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jade Biosciences, Inc.

Report date July 31, 2024 · Filed August 02, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,252 Ending reported balance After 2024-08-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2024-07-31 · Exercise / conversion · Acquired 11,454 · Balance 12,745

Row 2 · 2024-08-01 · Exercise / conversion · Acquired 1,507 · Balance 14,252

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03Direct0 Reported balance After 2024-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-07-31 · Exercise / conversion · Disposed 906 · Balance 0

F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03Direct1,507 Reported balance After 2024-07-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-07-31 · Exercise / conversion · Disposed 10,548 · Balance 1,507

F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03Direct0 Reported balance After 2024-08-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-08-01 · Exercise / conversion · Disposed 1,507 · Balance 0

F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 22, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 6,970 $2.14 $14,915.80
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,673

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,412 $1.74 $4,196.88
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
September 07, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 30 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 10

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,226

Underlying: Common Stock · 30 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
September 07, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 30 $15.01 $450.30
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
September 07, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 30 $2.14 $64.20
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,321

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 500 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 9

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,256

Underlying: Common Stock · 500 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,018 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 8

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,350

Underlying: Common Stock · 1,018 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,575

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 906 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,622

Underlying: Common Stock · 906 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 3,931 $15.06 $59,186.71
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 1,518 $2.14 $3,248.52
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,413 $1.74 $4,198.62
Disclosure

SEC source: 0001415889-23-013130 · form4-09082023_060901.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,853 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 8

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,756

Underlying: Common Stock · 6,853 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,018 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,368

Underlying: Common Stock · 1,018 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,082

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 905 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,528

Underlying: Common Stock · 905 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 541 $16.25 $8,788.60
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.175 to $16.470, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 9,742 $15.48 $150,791.55
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,832

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.17 to $16.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 7,871 $2.14 $16,843.94
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,574

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,412 $1.74 $4,196.88
Disclosure

SEC source: 0001415889-23-011986 · form4-08092023_060801.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
July 06, 2023 Filed Jul 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,852 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,609

Underlying: Common Stock · 6,852 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
July 06, 2023 Filed Jul 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,019 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,386

Underlying: Common Stock · 1,019 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
July 06, 2023 Filed Jul 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,506 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,589

Underlying: Common Stock · 1,506 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
July 06, 2023 Filed Jul 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 906 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-010966 · form4-07072023_060704.xml · derivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,433

Underlying: Common Stock · 906 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
July 06, 2023 Filed Jul 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 10,283 $16.66 $171,283.93
Disclosure

SEC source: 0001415889-23-010966 · form4-07072023_060704.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.31 to $17.225, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 06, 2023 Filed Jul 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 7,871 $2.14 $16,843.94
Disclosure

SEC source: 0001415889-23-010966 · form4-07072023_060704.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,574

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
July 06, 2023 Filed Jul 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,412 $1.74 $4,196.88
Disclosure

SEC source: 0001415889-23-010966 · form4-07072023_060704.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,853 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 8

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 164,461

Underlying: Common Stock · 6,853 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,018 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,405

Underlying: Common Stock · 1,018 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,095

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 905 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,339

Underlying: Common Stock · 905 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 15 $16.98 $254.63
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 10,268 $16.28 $167,160.99
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,306

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.84 to $16.82, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 7,871 $2.14 $16,843.94
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,574

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,412 $1.74 $4,196.88
Disclosure

SEC source: 0001415889-23-009448 · form4-06082023_060620.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,853 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 8

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,314

Underlying: Common Stock · 6,853 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F8 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,018 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,423

Underlying: Common Stock · 1,018 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F7 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,602

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 906 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,244

Underlying: Common Stock · 906 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 1,599 $22.74 $36,354.54
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.15 to $23.12, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 8,685 $21.62 $187,805.31
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,890

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.12 to $22.10, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 7,871 $2.14 $16,843.94
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
May 08, 2023 Filed May 9, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,413 $1.74 $4,198.62
Disclosure

SEC source: 0001415889-23-007686 · form4-05092023_060505.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · balance_after: Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).

Read SEC document
April 06, 2023 Filed Apr 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,852 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,167

Underlying: Common Stock · 6,852 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
April 06, 2023 Filed Apr 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,019 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,441

Underlying: Common Stock · 1,019 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
April 06, 2023 Filed Apr 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,109

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
April 06, 2023 Filed Apr 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 905 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-006377 · form4-04072023_060403.xml · derivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,150

Underlying: Common Stock · 905 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
April 06, 2023 Filed Apr 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 10,283 $18.17 $186,828.74
Disclosure

SEC source: 0001415889-23-006377 · form4-04072023_060403.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.785 to $18.58, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 06, 2023 Filed Apr 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 7,871 $2.14 $16,843.94
Disclosure

SEC source: 0001415889-23-006377 · form4-04072023_060403.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,283

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
April 06, 2023 Filed Apr 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,412 $1.74 $4,196.88
Disclosure

SEC source: 0001415889-23-006377 · form4-04072023_060403.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,412

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.